Comparative Pharmacology
Head-to-head clinical analysis: AVIANE 21 versus AVIANE 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVIANE 21 versus AVIANE 28.
AVIANE-21 vs AVIANE-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; inhibits gonadotropin secretion, suppressing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol is an estrogen, levonorgestrel is a progestin. Suppresses gonadotropins (FSH, LH), inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
One tablet orally once daily for 21 consecutive days, followed by 7 drug-free days. Each tablet contains levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg.
1 tablet (0.1 mg levonorgestrel/0.02 mg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 placebo tablets).
None Documented
None Documented
Levonorgestrel: terminal half-life 27.7 ± 7.2 hours; ethinyl estradiol: terminal half-life 15.4 ± 8.4 hours. Steady-state achieved within 7–14 days.
Terminal elimination half-life is 12-14 hours; steady-state achieved within 3 days; clinical significance: dosing interval every 12 hours.
Renal (primarily as metabolites, ~60%), fecal (~40%), with less than 10% excreted unchanged as ethinyl estradiol and levonorgestrel.
Renal: 50-60% as unchanged drug; Hepatic metabolism: 30-40% as inactive metabolites; Fecal: 10-20%.
Category C
Category C
Contraceptive (Hormonal)
Contraceptive (Hormonal)